🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

101,14 USD

Máx. histórico

123,62

846 días

Caída desde máximo

-18,18%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,34%

Cierre anterior

100,80

Rango de hoy

100,88 – 101,27

Volumen hoy

1.095.277

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,43%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,37 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 13 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
22/11/2022 57,62 58,26 56,26 57,92 +0,94% 3,47% 744.500
21/11/2022 57,26 59,09 56,80 57,38 -0,55% 4,00% 884.600
18/11/2022 56,47 58,21 56,23 57,70 +4,70% 3,52% 950.900
17/11/2022 54,79 55,88 54,00 55,11 -1,27% 3,43% 842.700
16/11/2022 58,50 58,52 55,63 55,82 -5,47% 4,94% 904.600
15/11/2022 59,00 60,90 58,91 59,05 +3,14% 3,37% 1.080.700
14/11/2022 56,24 58,36 55,09 57,25 +1,38% 5,81% 1.554.900
11/11/2022 59,73 60,68 55,87 56,47 -5,39% 8,06% 1.336.200
10/11/2022 59,76 60,62 58,31 59,69 +6,88% 3,86% 965.800
09/11/2022 56,36 58,56 55,76 55,85 -2,10% 4,97% 898.300
08/11/2022 56,63 59,01 55,36 57,05 +1,37% 6,44% 1.694.600
07/11/2022 60,89 61,29 54,18 56,28 -7,13% 11,67% 2.782.500
04/11/2022 61,19 61,67 59,03 60,60 +0,92% 4,31% 1.493.100
03/11/2022 64,09 70,11 59,94 60,05 -12,83% 15,87% 3.108.900
02/11/2022 72,50 72,50 68,14 68,89 -5,27% 6,01% 1.305.000
01/11/2022 74,46 74,66 72,23 72,72 -1,72% 3,27% 940.100
31/10/2022 75,16 75,52 73,21 73,99 -1,94% 3,07% 718.500
28/10/2022 73,95 76,11 73,23 75,45 +1,95% 3,89% 823.500
27/10/2022 76,85 77,14 73,94 74,01 -2,49% 4,16% 668.300
26/10/2022 75,16 77,15 74,64 75,90 +2,08% 3,34% 663.200
25/10/2022 73,13 75,59 73,12 74,35 +2,59% 3,38% 665.700
24/10/2022 73,17 73,20 69,96 72,47 +0,19% 4,43% 697.600
21/10/2022 71,60 72,54 69,13 72,33 +0,86% 4,76% 648.100
20/10/2022 70,19 73,51 69,41 71,71 +1,64% 5,84% 706.700
19/10/2022 71,81 72,55 70,34 70,55 -2,93% 3,08% 818.400
18/10/2022 73,14 74,51 71,74 72,68 +1,52% 3,79% 736.200
17/10/2022 70,50 72,21 70,26 71,59 +3,99% 2,77% 722.200
14/10/2022 71,51 71,95 67,50 68,84 -2,96% 6,22% 822.600
13/10/2022 67,57 72,13 66,16 70,94 +4,75% 8,84% 1.446.500
12/10/2022 67,60 68,14 65,79 67,72 +1,01% 3,48% 1.006.300